Matinas BioPharma
MTNB
37 hedge funds and large institutions have $16.6M invested in Matinas BioPharma in 2019 Q3 according to their latest regulatory filings, with 7 funds opening new positions, 8 increasing their positions, 4 reducing their positions, and 17 closing their positions.
100% more repeat investments, than reductions
Existing positions increased: 8 | Existing positions reduced: 4
0.13% less ownership
Funds ownership: 0.45% → 0.32% (-0.13%)
21% less funds holding
Funds holding: 47 → 37 (-10)
40% less capital invested
Capital invested by funds: $27.7M → $16.6M (-$11.1M)
59% less first-time investments, than exits
New positions opened: 7 | Existing positions closed: 17
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BBA
Baker Bros. Advisors
New York
|
+$1.43M |
| 2 |
SCA
STALEY CAPITAL ADVISERS
Pittsburgh,
Pennsylvania
|
+$145K |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
+$133K |
| 4 |
WG
Winton Group
London,
United Kingdom
|
+$126K |
| 5 |
Geode Capital Management
Boston,
Massachusetts
|
+$88.4K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
VC
Vivo Capital
Palo Alto,
California
|
-$5.84M |
| 2 |
BC
Broadfin Capital
New York
|
-$657K |
| 3 |
SCM
Stonepine Capital Management
Bend,
Oregon
|
-$573K |
| 4 |
Millennium Management
New York
|
-$132K |
| 5 |
TI
Telemetry Investments
New York
|
-$103K |
MTNB Hedge Fund Activity: Q3 2019 in Review
37 of the 4,560 institutional investors tracked by Wall St. Rank reported a position in Matinas BioPharma (MTNB) for Q3 2019, worth a combined $16.6M — down 40% from $27.7M a quarter earlier.
Sellers outnumbered buyers: 17 funds closed out of MTNB and 7 opened new positions — a net loss of 10 holders — while 4 trimmed existing stakes and 8 added.
The largest buyer was Baker Bros. Advisors, opening a new position worth an estimated $1.43M. The largest seller was Vivo Capital, exiting entirely with an estimated $5.84M sold.
- 37 institutional investors held Matinas BioPharma (MTNB) as of Q3 2019, down from 47 in Q2 2019.
- Funds reported $16.6M of Matinas BioPharma stock for Q3 2019, down 40% quarter-over-quarter.
- 7 funds opened new Matinas BioPharma positions in Q3 2019 and 17 closed out, a net change of -10 holders.
- The largest Matinas BioPharma buyer in Q3 2019 was Baker Bros. Advisors, an estimated $1.43M added.
- The largest Matinas BioPharma seller in Q3 2019 was Vivo Capital, an estimated $5.84M sold.
Based on aggregated 13F filings for Q3 2019.